Eli Lilly’s weight-loss drug helps nearly 99% of patients remain diabetes-free

Eli Lilly (LLY.N) said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.

The results suggest that tirzepatide – the active ingredient in Lilly’s diabetes drug Mounjaro and weight-loss treatment Zepbound – could prevent one new case of diabetes for every nine patients treated.